Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14 October 2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following separate full reviews, the Scottish Medicines Consortium (SMC) has approved two of its medicines for use by NHS Scotland.

“As a company we are committed to developing innovative new medicines. So the fact the SMC has decided two of our medicines are clinically effective and represent value for money for use within the NHS in Scotland on the same day is testament to this,” the company stated.

The two medicines approved for use on the National Health Service in Scotland are:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK